Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03715972 · ClinicalTrials.gov registry record
Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia
A clinical trial of Sickle Cell Disease and Thalassemia, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- 165
- Enrollment target
- 1
- Study location
NCT03715972 is a study of Sickle Cell Disease and Thalassemia that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 165 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03715972, a study of Sickle Cell Disease and Thalassemia, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its flow in response to stress) is altered in patients with chronic anemia. Since this parameter may depend on anemia severity, we will perform the MRI monitoring prior to and following clinically indicated transfusions in a subset of patients. Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose. The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients as well as 40 control subjects recruited from first degree relatives of the sickle cell disease population. All eligible subjects will be asked to provide informed consent before participating in the study.
Conditions Studied
Interventions
- DRUG Hydroxyurea
- DRUG Acetazolamide
Study Locations (1)
California
- CHLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03715972
The ClinicalTrials.gov registry entry for NCT03715972 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (43% lower). The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.
NCT03715972 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03715972 about?
NCT03715972 is a clinical study titled "Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia". This is primarily an observational trial in patients with chronic anemia syndromes (sickle cell disease and thalassemia) and control subjects. The key purpose is to understand how brain blood flow reserve (the ability of the brain to increase its flow in response to stress) is altered in patients wi...
What is the current status of trial NCT03715972?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2018-07-15. Estimated completion is 2022-12-31.
What conditions does trial NCT03715972 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Thalassemia, Healthy (Controls).
What interventions are being tested in trial NCT03715972?
The interventions under investigation include: Hydroxyurea (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03715972?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03715972 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.